SCHEMBL111178

SCHEMBL111178

C1=CN2CCNCC2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18950336 0.66
SCHEMBL15017679 0.64
Hydrochloric Acid SCHEMBL2797657 0.64
SCHEMBL108473 0.64
SCHEMBL16529635 0.61
SCHEMBL2360410 0.60
SCHEMBL9784554 0.59
SCHEMBL6406378 0.58
SCHEMBL4077331 0.57
SCHEMBL23478571 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030555-B1 NOVEL PYRAZINE AMIDE COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2019-01-30 EP claimed
EP-3030555-A1 NOVEL PYRAZINE AMIDE COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2016-06-15 EP claimed
US-9096548-B2 Pyrazine amide compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-08-04 US claimed
WO-2015018754-A1 NOVEL PYRAZINE AMIDE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-12 WO claimed
US-20150045326-A1 NOVEL PYRAZINE AMIDE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-12 US claimed
EP-2424867-A1 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2012-03-07 EP claimed
WO-2010125101-A1 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO claimed
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 US disclosed
US-12552807-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-02-17 US disclosed
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds PFIZER INC. (US) 2025-10-16 US disclosed
EP-4077306-B1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2025-05-07 EP disclosed
EP-4470609-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2024-12-04 EP disclosed
WO-2010125101-A1 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed
WO-2009095254-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
US-7307164-B2 β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2007-12-11 US disclosed
EP-1490335-B1 BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2007-09-19 EP disclosed
US-7022704-B2 5,6,7, 8-tetrahydro-imidazo-(1,2a)-pyrazine derivative; useful for treating restenosis and tumor SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2006-04-04 US disclosed
US-20050107390-A1 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME CORP. 2005-05-19 US disclosed
US-20040157891-A1 Inhibitor of cox FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed